July 28, 2020 Working paper Open Access

Sparavigna, Amelia Carolina

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.3964519</identifier>
  <creators>
    <creator>
      <creatorName>Sparavigna, Amelia Carolina</creatorName>
      <givenName>Amelia Carolina</givenName>
      <familyName>Sparavigna</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0003-4502-8974</nameIdentifier>
      <affiliation>Politecnico di Torino</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Ivermectin for Covid-19</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2020</publicationYear>
  <subjects>
    <subject>Covid-19</subject>
    <subject>Ivermectin</subject>
    <subject>Hydroxychloroquine</subject>
    <subject>Doxycycline</subject>
    <subject>azithromycin</subject>
    <subject>Covid-19 rare symptoms</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2020-07-28</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="Text">Working paper</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3964519</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3893750</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/covid-19</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/zenodo</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Discussion of scholarly papers published on Ivermectin, starting from the article of Caly et al. in Antiviral Research, available online April 3, 2020, and of some news that we can find about the use of this drug for the treatment of Covid-19. A list of clinical trials is also given. The proposed discussion was made in a series of versions from 14 June this of 28 July 2020.&amp;nbsp; For what concerns scholarly papers, we report among them a preprint posted on 10 June in MedR&amp;chi;iv,&amp;nbsp; which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.&amp;nbsp; We report also the preprint, posted on 8 July in MedR&amp;chi;iv too, showing the result of a clinical trial. This preprint tells, in its conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospitalization. Among news, we consider especially the news regarding the use of Ivermectin in Peru. The case of Iquitos is discussed in detail. In Iquitos, capital of the Department of Loreto, by May 25 Covid-19 cases and deaths had dropped notably, as reported on the web. Epidemic data in this region are considered. Recent news (July 27), displaying the observation of&amp;nbsp; rare symptoms of Covid-19, is also reported in detail. The observation was related to a set of more than 3,000 patients in Lima. The formulation of Ivermectin used in Peru is also discussed, in particular that of the oral solution, disclosed by the Peruvian Government.&amp;nbsp;&lt;/p&gt;</description>
    <description descriptionType="Other">Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.</description>
  </descriptions>
</resource>